Beyond API-CAT: The remaining challenges of extended anticoagulation for cancer-associated thrombosis

European Heart Journal - Cardiovascular Pharmacotherapy · Published 2026-07-20 · DOI 10.1093/ehjcvp/pvag054

Free full text

Authors (2)

Marcello Di Nisio, Tzu-Fei Wang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Nisio, M., Wang, T. (2026). Beyond API-CAT: The remaining challenges of extended anticoagulation for cancer-associated thrombosis. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvag054

Related articles

• Beta-blockers after myocardial infarction: time to change the guidelines · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why does research integrity affect us all? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Innovation and constraints in cardiovascular pharmacotherapy · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Why cardio-rheumatology? · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Real-world evidence of finerenone in Type 2 diabetes: addressing confounding and follow-up duration · European Heart Journal - Cardiovascular Pharmacotherapy · 2025 · Same journal
• Different aspects of myocardial intervention and pharmacological treatment · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal
• Beyond the review: additional non-oncologic drugs with clinically significant cardiovascular effects · European Heart Journal - Cardiovascular Pharmacotherapy · 2026 · Same journal